Abivax SA: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Abivax SA Unternehmen

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Abivax SA Informationen



BörsenkürzelABVX

Name des UnternehmensAbivax SA

IPO-datumJun 26, 2015

CEOde Garidel (Marc)

Anzahl der mitarbeiter- -

WertpapierartDepository Receipt

Geschäftsjahresende- -

Addresse7-11 Boulevard Haussmann

StadtPARIS

BörseNASDAQ OMX - NASDAQ BASIC

LandFrance

Postleitzahl75009

Telefon33153830963

Websitehttps://www.abivax.com/

BörsenkürzelABVX

IPO-datumJun 26, 2015

CEOde Garidel (Marc)

Führungskräfte von Abivax SA



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Pierre Courteille

Chief Business Officer

--

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

--

Mr. Didier Bruno Blondel

Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors

--

Ms. Corinna Zur Bonsen-Thomas

Independent Director

--

Mr. Kinam Hong

Director, Representative of Sofinnova Partners

--

Mr. Jerome Denis, Ph.D.

Executive Vice President - Process Development & Manufacturing

--

Mr. Marc de Garidel

Chief Executive Officer

--

Ms. Ida Hatoum

Chief People Officer, Chief Compliance Officer

--

Dr. June H. Lee, M.D.

Independent Director

--

Mr. Troy A. Ignelzi

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Pierre Courteille

Chief Business Officer

--

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

--

Mr. Didier Bruno Blondel

Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors

--

Ms. Corinna Zur Bonsen-Thomas

Independent Director

--

Mr. Kinam Hong

Director, Representative of Sofinnova Partners

--

Mr. Jerome Denis, Ph.D.

Executive Vice President - Process Development & Manufacturing

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Mon, Jan 19

Aktionäre

Aktionärstypen

Aktionäre

Anteil

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.01%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

Andere

73.39%

Aktionäre

Anteil

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.01%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

Andere

73.39%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

33.85%

Investment Advisor

23.60%

Investment Advisor/Hedge Fund

8.93%

Research Firm

2.98%

Venture Capital

2.18%

Private Equity

1.77%

Pension Fund

1.00%

Bank and Trust

0.02%

Andere

25.67%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

216

53.64M

52.23%

+104.02K

2025Q3

210

53.54M

52.22%

+19.70M

2025Q2

81

30.74M

57.27%

-1.09M

2025Q1

75

31.82M

50.24%

-38.10K

2024Q4

68

29.91M

44.59%

+2.48M

2024Q3

54

27.43M

45.93%

-700.83K

2024Q2

51

33.52M

46.25%

-227.21K

2024Q1

46

28.78M

34.33%

+7.18M

2023Q4

33

27.04M

1.75%

+20.54M

2023Q3

1

5.40M

0.00%

--

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

TCG Crossover Management, LLC

7.11M

9.67%

+1.05M

+17.42%

Sep 30, 2025

UBS Financial Services, Inc.

4.46M

6.06%

+4.29M

+2560.74%

Sep 30, 2025

Darwin Global Management Ltd

3.16M

4.3%

+3.16M

--

Sep 30, 2025

Point72 Asset Management, L.P.

2.93M

3.98%

+2.76M

+1642.45%

Sep 30, 2025

Cormorant Asset Management, LP

1.95M

2.65%

-180.00K

-8.45%

Sep 30, 2025

Paradigm BioCapital Advisors LP

1.56M

2.13%

+1.56M

--

Sep 30, 2025

Caligan Partners, LP

1.45M

1.97%

-222.48K

-13.29%

Sep 30, 2025

Fidelity Management & Research Company LLC

1.43M

1.94%

+417.90K

+41.26%

Sep 30, 2025

Fred Alger Management, LLC

1.23M

1.67%

+40.31K

+3.38%

Dec 31, 2025

Adar1 Capital Management LLC

1.35M

1.84%

-1.72M

-56.02%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Simplify Health Care ETF

2.86%

Harbor Health Care ETF

0.7%

Fidelity Nasdaq Composite Index ETF

0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

0%

Innovator IBD Breakout Opportunities ETF

0%

Simplify Health Care ETF

Anteil2.86%

Harbor Health Care ETF

Anteil0.7%

Fidelity Nasdaq Composite Index ETF

Anteil0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

Anteil0%

Innovator IBD Breakout Opportunities ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten